Antonio P Strafella
Overview
Explore the profile of Antonio P Strafella including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
175
Citations
5110
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rosal A, Martin S, Strafella A
Front Neurosci
. 2025 Mar;
19:1515374.
PMID: 40052092
Cognitive impairment is a prevalent non-motor symptom of Parkinson's disease (PD), increasing the risk of dementia as the disease progresses. Despite its clinical significance, the etiology of cognitive impairment in...
2.
Dennis A, Strafella A
Front Neurosci
. 2024 Oct;
18:1446878.
PMID: 39403068
Introduction: Parkinson's disease (PD) is a neurodegenerative movement disorder causing severe disability and cognitive impairment as the disease progresses. It is necessary to develop biomarkers for cognitive decline in PD...
3.
Advancing Parkinson's Disease Research in Canada: The Canadian Open Parkinson Network (C-OPN) Cohort
Cressatti M, Pinilla-Monsalve G, Blais M, Normandeau C, Degroot C, Kathol I, et al.
J Parkinsons Dis
. 2024 Sep;
14(7):1481-1494.
PMID: 39302382
Background: Enhancing the interactions between study participants, clinicians, and investigators is imperative for advancing Parkinson's disease (PD) research. The Canadian Open Parkinson Network (C-OPN) stands as a nationwide endeavor, connecting...
4.
Dzialas V, Doering E, Eich H, Strafella A, Vaillancourt D, Simonyan K, et al.
Mov Disord
. 2024 Sep;
39(12):2130-2143.
PMID: 39235364
In recent years, many neuroimaging studies have applied artificial intelligence (AI) to facilitate existing challenges in Parkinson's disease (PD) diagnosis, prognosis, and intervention. The aim of this systematic review was...
5.
Dennis A, Strafella A
Parkinsonism Relat Disord
. 2024 May;
126:106986.
PMID: 38724317
Parkinson's disease is a neurodegenerative movement disorder associated with motor and non-motor symptoms causing severe disability as the disease progresses. The development of biomarkers for Parkinson's disease to diagnose patients...
6.
Kon T, Ichimata S, Di Luca D, Martinez-Valbuena I, Kim A, Yoshida K, et al.
Brain Commun
. 2024 May;
6(3):fcae141.
PMID: 38712319
Multiple system atrophy is a neurodegenerative disease with α-synuclein pathology predominating in the striatonigral and olivopontocerebellar systems. Mixed pathologies are considered to be of low frequency and mostly comprise primary...
7.
Pasternak M, Mirza S, Luciw N, Mutsaerts H, Petr J, Thomas D, et al.
Alzheimers Dement
. 2024 Apr;
20(5):3525-3542.
PMID: 38623902
Introduction: Effective longitudinal biomarkers that track disease progression are needed to characterize the presymptomatic phase of genetic frontotemporal dementia (FTD). We investigate the utility of cerebral perfusion as one such...
8.
Oltra J, Segura B, Strafella A, van Eimeren T, Ibarretxe-Bilbao N, Diez-Cirarda M, et al.
NPJ Parkinsons Dis
. 2024 Mar;
10(1):69.
PMID: 38521776
Clinical, cognitive, and atrophy characteristics depending on sex have been previously reported in Parkinson's disease (PD). However, though sex differences in cortical gray matter measures in early drug naïve patients...
9.
Peralta C, Strafella A, Kim H
Mov Disord Clin Pract
. 2024 Jan;
11(1):10-13.
PMID: 38291843
No abstract available.
10.
Mena A, Chen R, Graff-Guerrero A, Martin S, Uribe C, Strafella A
Mov Disord Clin Pract
. 2023 Dec;
10(12):1725-1737.
PMID: 38094644
Background: Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are atypical parkinsonisms (APs) that are classified as tauopathies. Patients with these APs may present with similar early clinical manifestations to...